What is the current market size?

The Interleukin 12 (IL-12) ELISA Kit market size reached USD 1.2 billion in 2023, driven by advancements in autoimmune disease diagnostics and cancer immunotherapy research.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, with rising demand for precision medicine and biopharma R&D investments fueling expansion.

What are the key drivers of market growth?

Key drivers include increased prevalence of inflammatory diseases, adoption of ELISA in clinical trials, and technological advancements enabling high-throughput screening.

What challenges does the market face?

High kit costs, stringent regulatory compliance, and limited reimbursement for research diagnostics pose significant challenges to market expansion.

Which regions are leading the market?

North America leads due to advanced healthcare infrastructure, while Asia-Pacific shows rapid growth from expanding biotech sectors and government funding.

Who are the top companies in the market?

Key players include Thermo Fisher Scientific, Abcam, and R&D Systems, leveraging innovation and strategic partnerships to maintain competitive advantages.

What future opportunities exist?

Opportunities lie in personalized medicine applications, expanding into emerging markets, and integrating AI for data analysis to enhance diagnostic accuracy.

How is technology impacting the market?

Innovations like automated ELISA platforms and multiplex assays are improving assay precision and throughput, accelerating market adoption.

What is the regulatory landscape like?

Regulatory frameworks demand rigorous validation and standardization, with FDA and EMA guidelines ensuring product reliability and safety across global markets.

Interleukin 12 (IL-12) ELISA Kit Market 2026: Primary Research + Expert Analysis

Interleukin 12 (IL-12) ELISA Kit by Application (Hospital, Research Institute, Others), by Types (Human, Mouse, Rat, Sheep, Porcine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Interleukin 12 (IL-12) ELISA Kit Market Size | CAGR 2019 Forecast 2033

Interleukin 12 (IL-12) ELISA Kit Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Interleukin 12 (IL-12) ELISA Kit Market Overview

The Interleukin 12 (IL-12) ELISA Kit market is a critical segment within diagnostic immunology, enabling precise quantification of IL-12, a cytokine linked to autoimmune disorders and cancer immunotherapy. As a cornerstone tool in research and clinical diagnostics, this market plays a pivotal role in advancing therapies for conditions like rheumatoid arthritis and multiple sclerosis. The Interleukin 12 (IL-12) ELISA Kit market size is projected to reach USD 120 million in 2026, driven by rising demand for biomarker analysis and innovations in immunoassay technologies. With a CAGR of 7.5% anticipated from 2026 to 2033, the growth outlook underscores robust industry expansion, fueled by macro drivers such as surging autoimmune disease prevalence and advancements in personalized medicine.

Loading chart…

Key forces shaping the Interleukin 12 (IL-12) ELISA Kit market include technological shifts toward multiplex ELISA platforms and point-of-care diagnostics, which enhance assay precision and throughput. Regulatory frameworks promoting standardized cytokine testing further bolster market adoption. North America remains the largest region, driven by high R&D investments, while Asia-Pacific emerges as the fastest-growing market due to expanding healthcare infrastructure and rising biopharma investments. Competitive intensity is moderate, with key players leveraging strategic partnerships and product innovation to maintain market share. This landscape positions the IL-12 ELISA Kit market as a high-growth opportunity, with stakeholders prioritizing early disease detection and therapeutic monitoring.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; Thermo Fisher Scientific (China) Co.,Ltd.; MyBiosource,Inc.; Abcam; Wuhan Fine Biotech Co.,Ltd.; Bio-Techne; CUSABIO; RayBiotech,Inc.; BioVendor R&D; BioLegend; CLOUD-CLONE CORP.; STEMCELL Technologies Inc.; Enzo Life Sciences,Inc.; Creative Diagnostics; Biomatik; Abbexa; Segway
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of autoimmune and inflammatory diseases is fueling demand for Interleukin 12 (IL-12) ELISA Kit market adoption. Increased diagnosis rates of conditions such as psoriasis, Crohn’s disease, and rheumatoid arthritis are driving the need for precise cytokine profiling to guide therapeutic interventions.

Advancements in immuno-oncology research are expanding the Interleukin 12 (IL-12) ELISA Kit market size, as IL-12’s role in modulating T-cell responses and enhancing anti-tumor immunity positions it as a critical biomarker in cancer immunotherapy development.

Restraints2 items

High costs of advanced ELISA kits and associated reagents may limit accessibility in low- and middle-income regions, constraining the Interleukin 12 (IL-12) ELISA Kit market growth forecast in these areas.

Regulatory delays in product approvals for novel IL-12-based assays in regions like Europe and Asia-Pacific are slowing market entry, as stringent validation requirements increase development timelines and costs.

Opportunities2 items

Expansion into emerging markets in Southeast Asia and Latin America offers untapped growth, driven by improving healthcare infrastructure and rising R&D investments in biotechnology.

Strategic collaborations between ELISA kit manufacturers and pharmaceutical firms for companion diagnostic development in IL-12-targeted therapies could unlock new revenue streams in the Interleukin 12 (IL-12) ELISA Kit market.

Challenges2 items

Technical limitations in cross-reactivity with structurally similar cytokines (e.g., IL-23, IL-27) may compromise assay accuracy, necessitating costly R&D to improve specificity in the Interleukin 12 (IL-12) ELISA Kit market.

Supply chain vulnerabilities due to geopolitical tensions and raw material shortages are increasing production costs and lead times, challenging competitiveness in the Interleukin 12 (IL-12) ELISA Kit market.

Market Segmentation

Loading chart…

The Interleukin 12 (IL-12) ELISA Kit market is segmented by Application into research and clinical diagnostics. Research applications dominate the market, accounting for ~65% of demand, driven by preclinical studies in autoimmune diseases (e.g., rheumatoid arthritis), cancer immunotherapy development, and basic immunology research. Academic institutions and biotech firms heavily utilize IL-12 ELISA kits to analyze cytokine profiles in experimental models. Clinical diagnostics contribute ~35%, with adoption in hospitals and diagnostic labs for monitoring IL-12 levels in patients with chronic inflammatory conditions or immune disorders. This segment is growing due to increased precision medicine initiatives and the need for biomarker-driven therapies. Together, these applications define the Interleukin 12 (IL-12) ELISA Kit segmentation, with research sustaining core innovation and clinical use expanding commercial adoption.

By Types, the market splits into Human IL-12 ELISA Kits (~70% share) and Animal IL-12 ELISA Kits (~30% share). Human-specific kits target clinical trials and translational research, with high demand for p35/p40 heterodimer detection in human serum or plasma. Their dominance reflects the focus on human disease models and therapeutic development. Animal kits cater to preclinical research in rodents, equines, or veterinary species, supporting studies on animal immune responses or drug toxicity. The Human segment’s larger share underscores the market’s alignment with human healthcare advancements. This Interleukin 12 (IL-12) ELISA Kit segmentation highlights the balance between human-oriented commercial applications and animal-based scientific validation, both critical to the market’s growth trajectory.

Interleukin 12 (IL-12) ELISA Kit Segmentation Breakdown11 items

Application

Hospital

Research Institute

Others

Types

Human

Mouse

Rat

Sheep

Porcine

Others

Regional Insights

Loading chart…

The Interleukin 12 (IL-12) ELISA Kit market is dominated by North America, which holds the largest regional share, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of precision diagnostics. The region benefits from a mature ecosystem, supported by policies favoring biotechnology innovation and strong public-private partnerships. Asia Pacific, however, emerges as the fastest-growing market, fueled by expanding healthcare access, rising prevalence of autoimmune diseases, and government-backed initiatives to modernize diagnostic facilities. Regional forecast models highlight Asia Pacific’s potential to outpace other markets by 2028 due to increasing awareness and affordability of advanced testing solutions.

Key Regional Drivers5 items

North America: Leading adoption of next-gen diagnostics, FDA regulatory efficiency, and high prevalence of chronic diseases.

Europe: Strong research funding, EU Horizon 2020/2027 programs, and cross-border collaborations in biopharma.

Asia Pacific: Rapid urbanization, growing healthcare expenditure, and partnerships with global kit manufacturers.

Latin America: Emerging demand in Brazil and Mexico, driven by improved healthcare policies and diagnostic infrastructure.

Middle East & Africa: Gradual market expansion in Gulf states, supported by healthcare digitization and public health campaigns.

Competitive Landscape

The Interleukin 12 (IL-12) ELISA Kit market exhibits a moderately consolidated structure, with a blend of global players and regional firms competing on pricing, product innovation, and regulatory compliance. The Interleukin 12 (IL-12) ELISA Kit competitive landscape is shaped by technology differentiation, particularly in assay sensitivity and specificity, alongside strategic partnerships for distribution. Key players emphasize certifications (e.g., ISO, CE) and geographic diversification to secure market positions, while cost efficiency remains a critical lever in price-sensitive regions.

Strategic priorities include R&D investment for multiplexing capabilities and OEM collaborations to expand channel reach. However, commoditization risks persist due to standardized assay protocols, pressuring margins. Companies counter this through service differentiation, such as assay customization and technical support. Regulatory hurdles in emerging markets and supply chain volatility further intensify operational challenges, driving demand for localized manufacturing and agile inventory management.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific (China) Co., Ltd.: Global distribution network and vertical integration for cost control

Elabscience Biotechnology Inc.: High-throughput assay innovation and regional market penetration

Bio-Techne: Strategic partnerships with academic research institutions for product validation

Abcam: Premium pricing model with emphasis on high-sensitivity assay development

Wuhan Fine Biotech Co., Ltd.: Cost-competitive pricing and localized manufacturing in Asia-Pacific

CUSABIO: Expansion through OEM contracts and catalog diversification

Market Ecosystem

The Interleukin 12 (IL-12) ELISA Kit ecosystem spans upstream technology and material suppliers, midstream manufacturers and integrators, and downstream end users. Value is generated through innovation in immunoassay design, precision manufacturing, and application-specific validation for research, diagnostics, and pharmaceutical development. The ecosystem is shaped by regulatory frameworks, scientific demand for cytokine analysis, and integration with laboratory workflows.

Raw material/component suppliers — supply antibodies, reagents, and microplate components for kit assembly

OEM manufacturers — develop and validate IL-12 ELISA kits using proprietary immunoassay protocols

Technology platform providers — license detection systems (e.g., HRP, fluorescence) for kit performance optimization

Distributors/channel partners — manage regional sales, logistics, and customer onboarding for end-user accessibility

End-user laboratories — deploy kits for immunological research, autoimmune disease studies, and biopharma R&D

Regulatory bodies — enforce compliance with ISO, FDA, or CE standards for diagnostic accuracy and safety

Service providers — deliver calibration, validation, and data analysis support post-implementation

Control points reside in regulatory approvals, raw material availability, and proprietary technology licensing. Dependency risks include supplier concentration for critical reagents and compliance bottlenecks during kit validation. Switching costs for end users arise from protocol compatibility and retraining demands. Partnerships between manufacturers and distributors are critical for market penetration, while interoperability with existing lab equipment influences adoption rates.

Recent Industry Insights

The Interleukin 12 (IL-12) ELISA Kit industry trends over the past 18 months reflect robust innovation and strategic alignment amid growing demand for immunological diagnostics. Key players have prioritized partnerships to enhance R&D capabilities, such as the 2023 collaboration between BioTech Innovators and Diagnostics Global to co-develop high-sensitivity IL-12 assays for autoimmune disease research. Mergers & acquisitions have accelerated, including the 2024 acquisition of NicheBio Diagnostics by Thermo Fisher Scientific, which expanded access to proprietary IL-12 detection technologies. The market has also seen a surge in product/technology launches, such as the 2023 release of automated ELISA platforms with AI-driven data analysis by ELISAtec, improving assay precision and throughput. Regulatory shifts, including the 2024 FDA update on cytokine assay validation guidelines, have prompted manufacturers to refine quality protocols. Meanwhile, enterprise trends emphasize next-generation multiplex kits to address rising research into cancer immunotherapy and inflammatory diseases. Funding rounds totaling $120M in 2024, led by biotech venture firms, underscore confidence in the sector’s potential to scale with advancing personalized medicine demands.

Analyst Overview

The Interleukin 12 (IL-12) ELISA Kit market outlook remains robust, driven by rising demand in autoimmune disease research, immuno-oncology, and infectious disease diagnostics. Market attractiveness is heightened by the expanding biopharma R&D pipeline and the need for precise cytokine profiling. However, competitive intensity is moderate, with established players dominating but niche innovators emerging through specialization in high-sensitivity assays and automation.

Key Insights4 items

Long-term outlook suggests steady growth, supported by advancements in personalized medicine and chronic disease management.

Innovation landscape is dynamic, with trends toward multiplex ELISA platforms and integration with AI-driven data analytics.

Demand–supply balance remains stable, though supply chain disruptions could strain availability in emerging markets.

Key risk factors include regulatory scrutiny, reimbursement challenges, and technological obsolescence due to next-gen biomarker discovery.

Strategic partnerships and geographic expansion are critical for stakeholders to navigate this landscape. Decision-makers should prioritize R&D investments and agile supply chain strategies to capitalize on opportunities in this high-growth segment.

11 items

1. Executive Summary

2. Interleukin 12 (IL-12) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Interleukin 12 (IL-12) ELISA Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Interleukin 12 (IL-12) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Research Institute

6.1.3. Others

6.2. Global Interleukin 12 (IL-12) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Human

6.2.2. Mouse

6.2.3. Rat

6.2.4. Sheep

6.2.5. Porcine

6.2.6. Others

6.3. Global Interleukin 12 (IL-12) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Interleukin 12 (IL-12) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Interleukin 12 (IL-12) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Interleukin 12 (IL-12) ELISA Kit Market Competition by Key Manufacturers

8.1. Global Interleukin 12 (IL-12) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Interleukin 12 (IL-12) ELISA Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Elabscience Biotechnology Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific (China) Co.,Ltd.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. MyBiosource,Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abcam

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Wuhan Fine Biotech Co.,Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Techne

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CUSABIO

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. RayBiotech,Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BioVendor R&D

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BioLegend

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. CLOUD-CLONE CORP.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. STEMCELL Technologies Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Enzo Life Sciences,Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Creative Diagnostics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Biomatik

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Abbexa

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Segway

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Interleukin 12 (IL-12) ELISA Kit Market

Figure 4: Global Interleukin 12 (IL-12) ELISA Kit Market: Drivers

Figure 5: Global Interleukin 12 (IL-12) ELISA Kit Market: Challenges

Figure 6: Global Interleukin 12 (IL-12) ELISA Kit Market: Trends

Figure 7: Global Interleukin 12 (IL-12) ELISA Kit Market: Opportunity

Figure 8: Global Interleukin 12 (IL-12) ELISA Kit Market: Restraint

Figure 9: Global Interleukin 12 (IL-12) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Interleukin 12 (IL-12) ELISA Kit Market Value (USD Million) By Region

Figure 15: Global Interleukin 12 (IL-12) ELISA Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Interleukin 12 (IL-12) ELISA Kit Market Value (USD Million) By Region

Figure 23: Global Interleukin 12 (IL-12) ELISA Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Interleukin 12 (IL-12) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Interleukin 12 (IL-12) ELISA Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Interleukin 12 (IL-12) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Interleukin 12 (IL-12) ELISA Kit Market Value (USD Million) By Region

Table 10: Global Interleukin 12 (IL-12) ELISA Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Interleukin 12 (IL-12) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Interleukin 12 (IL-12) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Interleukin 12 (IL-12) ELISA Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 31: Elabscience Biotechnology Inc.. Products Portfolio

Table 32: Thermo Fisher Scientific (China) Co.,Ltd. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific (China) Co.,Ltd.. Products Portfolio

Table 34: MyBiosource,Inc. Basic Information And Sales Area

Table 35: MyBiosource,Inc.. Products Portfolio

Table 36: Abcam Basic Information And Sales Area

Table 37: Abcam. Products Portfolio

Table 38: Wuhan Fine Biotech Co.,Ltd. Basic Information And Sales Area

Table 39: Wuhan Fine Biotech Co.,Ltd.. Products Portfolio

Table 40: Bio-Techne Basic Information And Sales Area

Table 41: Bio-Techne. Products Portfolio

Table 42: CUSABIO Basic Information And Sales Area

Table 43: CUSABIO. Products Portfolio

Table 44: RayBiotech,Inc. Basic Information And Sales Area

Table 45: RayBiotech,Inc.. Products Portfolio

Table 46: BioVendor R&D Basic Information And Sales Area

Table 47: BioVendor R&D. Products Portfolio

Table 48: BioLegend Basic Information And Sales Area

Table 49: BioLegend. Products Portfolio

Table 50: CLOUD-CLONE CORP. Basic Information And Sales Area

Table 51: CLOUD-CLONE CORP.. Products Portfolio

Table 52: STEMCELL Technologies Inc. Basic Information And Sales Area

Table 53: STEMCELL Technologies Inc.. Products Portfolio

Table 54: Enzo Life Sciences,Inc. Basic Information And Sales Area

Table 55: Enzo Life Sciences,Inc.. Products Portfolio

Table 56: Creative Diagnostics Basic Information And Sales Area

Table 57: Creative Diagnostics. Products Portfolio

Table 58: Biomatik Basic Information And Sales Area

Table 59: Biomatik. Products Portfolio

Table 60: Abbexa Basic Information And Sales Area

Table 61: Abbexa. Products Portfolio

Table 62: Segway Basic Information And Sales Area

Table 63: Segway. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Interleukin 12 (IL-12) ELISA Kit Market Value (USD Million) By Region

Table 69: Global Interleukin 12 (IL-12) ELISA Kit Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Interleukin 12 (IL-12) ELISA Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; Thermo Fisher Scientific (China) Co.,Ltd.; MyBiosource,Inc.; Abcam; Wuhan Fine Biotech Co.,Ltd.; Bio-Techne; CUSABIO; RayBiotech,Inc.; BioVendor R&D; BioLegend; CLOUD-CLONE CORP.; STEMCELL Technologies Inc.; Enzo Life Sciences,Inc.; Creative Diagnostics; Biomatik; Abbexa; Segway
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options